Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM50-based multigene expression test Prosigna® in a p...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
5 August 2022
|
| In: |
International journal of molecular sciences
Year: 2022, Jahrgang: 23, Heft: 15, Pages: 1-17 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms23158716 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms23158716 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1422-0067/23/15/8716 
|
| Verfasserangaben: | Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F.H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi and Arndt Hartmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1838990356 | ||
| 003 | DE-627 | ||
| 005 | 20231128085904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230313s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms23158716 |2 doi | |
| 035 | |a (DE-627)1838990356 | ||
| 035 | |a (DE-599)KXP1838990356 | ||
| 035 | |a (OCoLC)1389534421 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Erber, Ramona |d 1988- |e VerfasserIn |0 (DE-588)1124557733 |0 (DE-627)878743936 |0 (DE-576)482825928 |4 aut | |
| 245 | 1 | 0 | |a Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting |c Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F.H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi and Arndt Hartmann |
| 264 | 1 | |c 5 August 2022 | |
| 300 | |b Diagramme | ||
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.03.2023 | ||
| 520 | |a In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM50-based multigene expression test Prosigna® in a prospective multicentric study. In 119/142 cases, Prosigna® molecular subtyping was compared with local and two central (C1 and C6) molecular-like subtypes relying on both immunohistochemistry (IHC; HRs, HER2, Ki-67) and IHC + tumor grade (IHC+G) subtyping. According to local IHC, 35.4% were Luminal A-like and 64.6% Luminal B-like subtypes (local IHC+G subtype: 31.9% Luminal A-like; 68.1% Luminal B-like). In contrast to local and C1 subtyping, C6 classified >2/3 of cases as Luminal A-like. Pairwise agreement between Prosigna® subtyping and molecular-like subtypes was fair to moderate depending on molecular-like subtyping method and center. The best agreement was observed between Prosigna® (53.8% Luminal A; 44.5% Luminal B) and C1 surrogate subtyping (Cohen’s kappa = 0.455). Adjuvant chemotherapy was suggested to 44.2% and 88.6% of Prosigna® Luminal A and Luminal B cases, respectively. Out of all Luminal A-like cases (locally IHC/IHC+G subtyping), adjuvant chemotherapy was recommended if Prosigna® testing classified as Prosigna® Luminal A at high / intermediate risk or upgraded to Prosigna® Luminal B. | ||
| 540 | |q DE-3 |a Namensnennung 4.0 International |f CC BY 4.0 |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a IHC | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a multigene expression analysis | |
| 650 | 4 | |a PAM50 | |
| 650 | 4 | |a Prosigna | |
| 650 | 4 | |a tumor grade | |
| 700 | 1 | |a Angeloni, Miriam |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stöhr, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lux, Michael P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ulbrich-Gebauer, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pelz, Enrico |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bankfalvi, Agnes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, Kurt W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Walter, Robert F. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vetter, Martina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomssen, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayr, Doris |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klauschen, Frederick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e VerfasserIn |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 700 | 1 | |a Sotlar, Karl |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stering, Katharina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Wunderle, Marius |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasching, Peter A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beckmann, Matthias W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kimmig, Rainer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harbeck, Nadia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wuerstlein, Rachel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferrazzi, Fulvia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hartmann, Arndt |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d Basel : Molecular Diversity Preservation International, 2000 |g 23(2022), 15, Artikel-ID 8716, Seite 1-17 |h Online-Ressource |w (DE-627)316340715 |w (DE-600)2019364-6 |w (DE-576)281194653 |x 1422-0067 |7 nnas |a Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:15 |g elocationid:8716 |g pages:1-17 |g extent:17 |a Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ijms23158716 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/1422-0067/23/15/8716 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230313 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 17 | ||
| 998 | |g 1022590944 |a Sinn, Peter |m 1022590944:Sinn, Peter |d 910000 |d 912000 |d 50000 |e 910000PS1022590944 |e 912000PS1022590944 |e 50000PS1022590944 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 14 | ||
| 999 | |a KXP-PPN1838990356 |e 4288535085 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"noteIll":"Diagramme","extent":"17 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F.H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi and Arndt Hartmann"]},"id":{"eki":["1838990356"],"doi":["10.3390/ijms23158716"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"5 August 2022"}],"recId":"1838990356","relHost":[{"origin":[{"publisherPlace":"Basel","dateIssuedKey":"2000","publisher":"Molecular Diversity Preservation International","dateIssuedDisp":"2000-"}],"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"issn":["1422-0067","1661-6596"],"zdb":["2019364-6"],"eki":["316340715"]},"disp":"Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world settingInternational journal of molecular sciences","part":{"volume":"23","issue":"15","text":"23(2022), 15, Artikel-ID 8716, Seite 1-17","year":"2022","extent":"17","pages":"1-17"},"titleAlt":[{"title":"IJMS"}],"recId":"316340715","pubHistory":["1.2000 -"],"language":["eng"],"note":["Gesehen am 17.09.20"],"title":[{"title_sort":"International journal of molecular sciences","title":"International journal of molecular sciences"}]}],"note":["Gesehen am 13.03.2023"],"title":[{"title":"Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting","title_sort":"Molecular subtyping of invasive breast cancer using a PAM50-based multigene expression test-comparison with molecular-like subtyping by tumor grade/immunohistochemistry and influence on oncologist’s decision on systemic therapy in a real-world setting"}],"language":["eng"],"person":[{"display":"Erber, Ramona","family":"Erber","role":"aut","given":"Ramona"},{"role":"aut","given":"Miriam","display":"Angeloni, Miriam","family":"Angeloni"},{"given":"Robert","role":"aut","family":"Stöhr","display":"Stöhr, Robert"},{"family":"Lux","display":"Lux, Michael P.","given":"Michael P.","role":"aut"},{"role":"aut","given":"Daniel","display":"Ulbrich-Gebauer, Daniel","family":"Ulbrich-Gebauer"},{"role":"aut","given":"Enrico","display":"Pelz, Enrico","family":"Pelz"},{"given":"Agnes","role":"aut","family":"Bankfalvi","display":"Bankfalvi, Agnes"},{"family":"Schmid","display":"Schmid, Kurt W.","given":"Kurt W.","role":"aut"},{"family":"Walter","display":"Walter, Robert F. H.","given":"Robert F. H.","role":"aut"},{"given":"Martina","role":"aut","family":"Vetter","display":"Vetter, Martina"},{"role":"aut","given":"Christoph","display":"Thomssen, Christoph","family":"Thomssen"},{"display":"Mayr, Doris","family":"Mayr","role":"aut","given":"Doris"},{"role":"aut","given":"Frederick","display":"Klauschen, Frederick","family":"Klauschen"},{"role":"aut","given":"Peter","display":"Sinn, Peter","family":"Sinn"},{"given":"Karl","role":"aut","family":"Sotlar","display":"Sotlar, Karl"},{"family":"Stering","display":"Stering, Katharina","given":"Katharina","role":"aut"},{"given":"Albrecht","role":"aut","family":"Stenzinger","display":"Stenzinger, Albrecht"},{"family":"Wunderle","display":"Wunderle, Marius","given":"Marius","role":"aut"},{"role":"aut","given":"Peter A.","display":"Fasching, Peter A.","family":"Fasching"},{"family":"Beckmann","display":"Beckmann, Matthias W.","given":"Matthias W.","role":"aut"},{"given":"Oliver","role":"aut","family":"Hoffmann","display":"Hoffmann, Oliver"},{"given":"Rainer","role":"aut","family":"Kimmig","display":"Kimmig, Rainer"},{"family":"Harbeck","display":"Harbeck, Nadia","given":"Nadia","role":"aut"},{"given":"Rachel","role":"aut","family":"Wuerstlein","display":"Wuerstlein, Rachel"},{"display":"Ferrazzi, Fulvia","family":"Ferrazzi","role":"aut","given":"Fulvia"},{"given":"Arndt","role":"aut","family":"Hartmann","display":"Hartmann, Arndt"}]} | ||
| SRT | |a ERBERRAMONMOLECULARS5202 | ||